GWN 323

Drug Profile

GWN 323

Alternative Names: GWN323

Latest Information Update: 23 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in Singapore (IV) after July 2016 (NCT02740270)
  • 01 Jul 2016 Phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in Canada (IV) (NCT02740270)
  • 11 Apr 2016 Novartis Pharmaceuticals plans a phase I/Ib trial for Solid tumours and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA, Spain, Singapore, United Kingdom and Canada (Parenteral) (NCT02740270)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top